Cargando…
Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea
Previous studies have reported the survival benefit after ruxolitinib treatment in patients with myelofibrosis (MF). However, population-based data of its efficacy are limited. We analyzed the effects of ruxolitinib in MF patients with data from the Korean National Health Insurance Database. In tota...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540308/ https://www.ncbi.nlm.nih.gov/pubmed/34682897 http://dx.doi.org/10.3390/jcm10204774 |
_version_ | 1784588955727953920 |
---|---|
author | Lee, Byung-Hyun Moon, Hyemi Chae, Jae-Eun Kang, Ka-Won Kim, Byung-Soo Lee, Juneyoung Park, Yong |
author_facet | Lee, Byung-Hyun Moon, Hyemi Chae, Jae-Eun Kang, Ka-Won Kim, Byung-Soo Lee, Juneyoung Park, Yong |
author_sort | Lee, Byung-Hyun |
collection | PubMed |
description | Previous studies have reported the survival benefit after ruxolitinib treatment in patients with myelofibrosis (MF). However, population-based data of its efficacy are limited. We analyzed the effects of ruxolitinib in MF patients with data from the Korean National Health Insurance Database. In total, 1199 patients diagnosed with MF from January 2011 to December 2017 were identified, of which 731 were included in this study. Patients who received ruxolitinib (n = 224) were matched with those who did not receive the drug (n = 507) using the 1:1 greedy algorithm. Propensity scores were formulated using five variables: age, sex, previous history of arterial/venous thrombosis, and red blood cell (RBC) or platelet (PLT) transfusion dependence at the time of diagnosis. Cox regression analysis for overall survival (OS) revealed that ruxolitinib treatment (hazard ratio (HR), 0.67; p = 0.017) was significantly related to superior survival. In the multivariable analysis for OS, older age (HR, 1.07; p < 0.001), male sex (HR, 1.94; p = 0.021), and RBC (HR, 3.72; p < 0.001) or PLT (HR, 9.58; p = 0.001) transfusion dependence were significantly associated with poor survival, although type of MF did not significantly affect survival. Considering evidence supporting these results remains weak, further studies on the efficacy of ruxolitinib in other populations are needed. |
format | Online Article Text |
id | pubmed-8540308 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85403082021-10-24 Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea Lee, Byung-Hyun Moon, Hyemi Chae, Jae-Eun Kang, Ka-Won Kim, Byung-Soo Lee, Juneyoung Park, Yong J Clin Med Article Previous studies have reported the survival benefit after ruxolitinib treatment in patients with myelofibrosis (MF). However, population-based data of its efficacy are limited. We analyzed the effects of ruxolitinib in MF patients with data from the Korean National Health Insurance Database. In total, 1199 patients diagnosed with MF from January 2011 to December 2017 were identified, of which 731 were included in this study. Patients who received ruxolitinib (n = 224) were matched with those who did not receive the drug (n = 507) using the 1:1 greedy algorithm. Propensity scores were formulated using five variables: age, sex, previous history of arterial/venous thrombosis, and red blood cell (RBC) or platelet (PLT) transfusion dependence at the time of diagnosis. Cox regression analysis for overall survival (OS) revealed that ruxolitinib treatment (hazard ratio (HR), 0.67; p = 0.017) was significantly related to superior survival. In the multivariable analysis for OS, older age (HR, 1.07; p < 0.001), male sex (HR, 1.94; p = 0.021), and RBC (HR, 3.72; p < 0.001) or PLT (HR, 9.58; p = 0.001) transfusion dependence were significantly associated with poor survival, although type of MF did not significantly affect survival. Considering evidence supporting these results remains weak, further studies on the efficacy of ruxolitinib in other populations are needed. MDPI 2021-10-18 /pmc/articles/PMC8540308/ /pubmed/34682897 http://dx.doi.org/10.3390/jcm10204774 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lee, Byung-Hyun Moon, Hyemi Chae, Jae-Eun Kang, Ka-Won Kim, Byung-Soo Lee, Juneyoung Park, Yong Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea |
title | Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea |
title_full | Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea |
title_fullStr | Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea |
title_full_unstemmed | Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea |
title_short | Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea |
title_sort | clinical efficacy of ruxolitinib in patients with myelofibrosis: a nationwide population-based study in korea |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540308/ https://www.ncbi.nlm.nih.gov/pubmed/34682897 http://dx.doi.org/10.3390/jcm10204774 |
work_keys_str_mv | AT leebyunghyun clinicalefficacyofruxolitinibinpatientswithmyelofibrosisanationwidepopulationbasedstudyinkorea AT moonhyemi clinicalefficacyofruxolitinibinpatientswithmyelofibrosisanationwidepopulationbasedstudyinkorea AT chaejaeeun clinicalefficacyofruxolitinibinpatientswithmyelofibrosisanationwidepopulationbasedstudyinkorea AT kangkawon clinicalefficacyofruxolitinibinpatientswithmyelofibrosisanationwidepopulationbasedstudyinkorea AT kimbyungsoo clinicalefficacyofruxolitinibinpatientswithmyelofibrosisanationwidepopulationbasedstudyinkorea AT leejuneyoung clinicalefficacyofruxolitinibinpatientswithmyelofibrosisanationwidepopulationbasedstudyinkorea AT parkyong clinicalefficacyofruxolitinibinpatientswithmyelofibrosisanationwidepopulationbasedstudyinkorea |